Comparative efficacy and safety of different combinations of three CDK4/6 inhibitors with endocrine therapies in HR+/HER-2 − metastatic or advanced breast cancer patients: a network meta-analysis

Comparative efficacy and safety of different combinations of three CDK4/6 inhibitors with endocrine therapies in HR+/HER-2 − metastatic or advanced breast cancer patients: a network meta-analysis

Abstract Background This network meta-analysis aimed to assess the comparative efficacy and safety of combinations involving three cyclin-dependent kinase 4/6 (CDK4/6) inhibitors and endocrine therapies (ETs) in patients with metastatic or advanced breast cancer (BC) who are hormone receptor-positiv...

Full description

Bibliographic Details
Main Authors:	Yiyuan Liu, Jinyao Wu, Zeqi Ji, Lingzhi Chen, Juan Zou, Jiehua Zheng, Weixun Lin, Jiehui Cai, Yaokun Chen, Daitian Zheng, Yexi Chen, Zhiyang Li
Format:	Article
Language:	English
Published:	BMC 2023-08-01
Series:	BMC Cancer
Subjects:	Breast cancer Abemaciclib Ribociclib Palbociclib Network meta-analysis
Online Access:	https://doi.org/10.1186/s12885-023-11322-2

Similar Items

Should All Patients With HR-Positive HER2-Negative Metastatic Breast Cancer Receive CDK 4/6 Inhibitor As First-Line Based Therapy? A Network Meta-Analysis of Data from the PALOMA 2, MONALEESA 2, MONALEESA 7, MONARCH 3, FALCON, SWOG and FACT Trials
by: Valentina Rossi, et al.
Published: (2019-10-01)

CDK 4/6 inhibitors combined with radiotherapy: A review of literature
by: Claire Bosacki, et al.
Published: (2021-01-01)

Late onset toxicities associated with the use of CDK 4/6 inhibitors in hormone receptor positive (HR+), human epidermal growth factor receptor-2 negative (HER2-) metastatic breast cancer patients: a multidisciplinary, pan-EU position paper regarding their optimal management. The GIOCONDA project
by: Marina Elena Cazzaniga, et al.
Published: (2023-10-01)

CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors
by: Francesco Schettini, et al.
Published: (2018-12-01)

Recent advances of highly selective CDK4/6 inhibitors in breast cancer
by: Hanxiao Xu, et al.
Published: (2017-04-01)

Expanding the Clinical Use of CDK4/6 Inhibitors in the Treatment of Hormone Receptor-Positive, HER2-Negative Breast Cancer from Metastatic Setting to Adjuvant Setting
by: Abdel-Razeq H, et al.
Published: (2022-03-01)

Digging in real-word electronic database for assessing CDK 4/6 inhibitors adherence in breast cancer patients from Romania
by: Adina Turcu-Stiolica, et al.
Published: (2024-02-01)

Resistance to CDK4/6 Inhibitors in Estrogen Receptor-Positive Breast Cancer
by: Erin R. Scheidemann, et al.
Published: (2021-11-01)

Efficacy of CDK 4/6 Inhibitors and Radiotherapy in Breast Cancer Patients with Brain Metastases
by: Marcin Kubeczko, et al.
Published: (2023-03-01)

Safety and Feasibility of Radiation Therapy Combined with CDK 4/6 Inhibitors in the Management of Advanced Breast Cancer
by: Marcin Kubeczko, et al.
Published: (2023-01-01)

Combined endocrine approaches vs endocrine therapy alone as first line treatment in elderly patients with hormone receptor-positive, HER2 negative, advanced breast cancer: to prescribe for the patient or the physician? A meta-analysis of phase II and III randomized clinical trials
by: Claudia Omarini, et al.
Published: (2020-05-01)

Clinical considerations of CDK4/6 inhibitors in HER2 positive breast cancer
by: Cui Zhang, et al.
Published: (2024-01-01)

Fulvestrant in Combination with CDK4/6 Inhibitors for HER2- Metastatic Breast Cancers: Current Perspectives
by: Iorfida M, et al.
Published: (2020-03-01)

Adjuvant CDK4/6 Inhibitors for Early Breast Cancer: How to Choose Wisely?
by: Elisa Agostinetto, et al.
Published: (2023-11-01)

Hematological Events Potentially Associated with CDK4/6 Inhibitors: An Analysis from the European Spontaneous Adverse Event Reporting System
by: Vera Martins, et al.
Published: (2023-09-01)

An Overview of the Safety Profile and Clinical Impact of CDK4/6 Inhibitors in Breast Cancer—A Systematic Review of Randomized Phase II and III Clinical Trials
by: Ioana-Miruna Stanciu, et al.
Published: (2023-09-01)

The Renaissance of CDK Inhibitors in Breast Cancer Therapy: An Update on Clinical Trials and Therapy Resistance
by: Mary Abdelmalak, et al.
Published: (2022-11-01)

Development and Validation of a Novel LC-MS/MS Method for the Simultaneous Determination of Abemaciclib, Palbociclib, Ribociclib, Anastrozole, Letrozole, and Fulvestrant in Plasma Samples: A Prerequisite for Personalized Breast Cancer Treatment
by: Lu Turković, et al.
Published: (2022-05-01)

Treatment options for patients with hormone receptor-positive, HER2-negative advanced-stage breast cancer: maintaining cyclin-dependent kinase 4/6 inhibitors beyond progression
by: Malek Horani, et al.
Published: (2023-10-01)

Selecting the optimal position of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer – the SONIA study: study protocol for a randomized controlled trial
by: A. van Ommen-Nijhof, et al.
Published: (2018-11-01)

Rapid Capillary Electrophoresis Method for Simultaneous Determination of Abemaciclib, Ribociclib, and Palbociclib in Pharmaceutical Dosage Forms: A Green Approach
by: Zvonimir Mlinarić, et al.
Published: (2022-11-01)

Economic Evaluation for Palbociclib Plus Fulvestrant vs Ribociclib Plus Fulvestrant and Abemaciclib Plus Fulvestrant in Endocrine-Resistant Advanced or Metastatic Breast Cancer in Italy
by: Colombo GL, et al.
Published: (2023-03-01)

The Association between Proton Pump Inhibitors and the Effectiveness of CDK Inhibitors in HR+/HER- Advanced Breast Cancer Patients: A Systematic Review and Meta-Analysis
by: Yu-Cheng Chang, et al.
Published: (2023-10-01)

The effect of low HER2 expression on treatment outcomes in metastatic hormone receptor positive breast cancer patients treated with a combination of a CDK4/6 inhibitor and endocrine therapy: A multicentric retrospective study
by: Eda Caliskan Yildirim, et al.
Published: (2023-08-01)

The effect of CDK4/6 inhibitors on the overall survival in patients with advanced HR+/HER2- BC in the entire population and in special clinical subgroups of unfavorable prognosis: A review
by: Katerina S. Grechukhina, et al.
Published: (2023-05-01)

CDK 4/6 inhibitors mired in uncertainty in HR positive and HER2 negative early breast cancer
by: Serena Di Cosimo, et al.
Published: (2021-02-01)

CDK4/6 Inhibitors—Overcoming Endocrine Resistance Is the Standard in Patients with Hormone Receptor-Positive Breast Cancer
by: Naiba Nabieva, et al.
Published: (2023-03-01)

<i>MYCN</i> Amplification, along with Wild-Type RB1 Expression, Enhances CDK4/6 Inhibitors’ Efficacy in Neuroblastoma Cells
by: Piergiuseppe De Rosa, et al.
Published: (2023-03-01)

Matching-adjusted indirect treatment comparison of ribociclib and palbociclib in HR+, HER2− advanced breast cancer
by: Tremblay G, et al.
Published: (2018-05-01)

Pharmacoeconomic analysis of using cyclin-dependent kinase 4 and 6 inhibitors in the first line treatment of HR-positive HER2-negative advanced breast cancer
by: N. A. Avxentyev, et al.
Published: (2020-02-01)

CDK4/6 Inhibitors in the First-Line Treatment of Postmenopausal Women with HR+/HER2− Advanced or Metastatic Breast Cancer: An Updated Network Meta-Analysis and Cost-Effectiveness Analysis
by: Ni Zeng, et al.
Published: (2023-06-01)

CDK4/6 Inhibitors in Melanoma: A Comprehensive Review
by: Mattia Garutti, et al.
Published: (2021-05-01)

Letter in Reply: indirect comparison of quality-of-life scores between patients with advanced breast cancer receiving palbociclib and abemaciclib in combination with fulvestrant
by: Ernest H Law, et al.
Published: (2023-04-01)

Letter to the Editor: statistics and clinical perception of patients’ reported outcomes for palbociclib and abemaciclib: a sliding doors story
by: Vittorio Gebbia
Published: (2023-04-01)

Stromal Senescence following Treatment with the CDK4/6 Inhibitor Palbociclib Alters the Lung Metastatic Niche and Increases Metastasis of Drug-Resistant Mammary Cancer Cells
by: Gregory T. Gallanis, et al.
Published: (2023-03-01)

Proton pump inhibitors may reduce the efficacy of ribociclib and palbociclib in metastatic breast cancer patients based on an observational study
by: Kadir Eser, et al.
Published: (2022-05-01)

Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy
by: Cengiz Karacin, et al.
Published: (2023-02-01)

Development of a SPE-LC-MS Method for the Quantitation of Palbociclib and Abemaciclib in Human Plasma
by: Daniela Maria Calucică, et al.
Published: (2022-12-01)

Clinical outcomes of cyclin-dependent kinase 4–6 (CDK 4–6) inhibitors in patients with male breast cancer: A multicenter study
by: Hasan Çağrı Yıldırım, et al.
Published: (2022-12-01)

Clinical Impact of CDK4/6 Inhibitors in De Novo or PR− or Very Elderly Post-Menopausal ER+/HER2− Advanced Breast Cancers
by: Hiu Tang, et al.
Published: (2023-10-01)